Syra Health Corp. Class A (SYRA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Syra Health Corp. Class A stock $0.13, price $0.80, that is 84.1% below the price, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
37‑month range $0.0521 – $4.85 · fair‑value band $0.0850 – $0.1615 · the $0.8010 price screens above the $0.1275 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Syra Health Corp. Class A Common Stock in your weekly email
Every Wednesday you see whether Syra Health Corp. Class A Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Syra Health Corp., a healthcare services company, provides solutions in behavioral and mental health, population health, digital health, health education and training, and healthcare workforce development and staffing in the United States.
Show moreShow less
The company offers Syrenity, a behavioral and mental health application that identifies and prevents the progression of negative factors that can influence individuals' mental health by offering targeted assignments, education, and monitoring symptoms, as well as providing interventions, such as cognitive behavioral therapy and mindfulness techniques; digital health products, including SyraBot, a chatbot to foster connectivity and engagement throughout individuals' care journeys offering members access to necessary information via its AI-powered customer support chat system; and CarePlus, an electronic medical records solution for small to mid-sized healthcare organizations.
It also provides analytics as a service, analytics as a service, epidemiology, and health equity analytics solutions.
In addition, the company offers medical communications, patient education, and healthcare training; and recruits nurses and allied health professionals for long-term fixed contract positions at hospitals and healthcare facilities.
It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. The company was incorporated in 2020 and is headquartered in Carmel, Indiana.
Stock analysis
Syra Health Corp. Class A (SYRA) currently trades at $0.8010, while our model-based Fair Value estimate is $0.1275, 84% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.0850 (bear) to $0.1615 (bull), the price of $0.8010 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Syra Health Corp. Class A Common Stock reported revenue of $7.2M in FY2025 versus $1.4M in FY2021, a compound +50.5%/yr. Reported net income was −$896K in FY2025.
Key figures
Market cap $11.1M Micro · P/E ratio 86.0 · P/S ratio 1.48 · Net margin 1.6% · Return on equity 5.2% · Return on assets (EBIT) −56.9% (5-year average) · Operating margin 10.5% · Revenue (TTM) $8.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 24 out of 100 (low confidence).
What moves the price
The share trades about 24% below its 52-week high and 1,235% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −84%, SYRA screens richer than that median.
Fair Value models
Bear$0.0850Fair Value $0.1275Bull$0.1615
Price $0.8010 · Downside -84.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham)$0.1000$0.1500$0.190052
All 1 models by family
Asset-Based
NCAV (Graham)$0.1000$0.1500$0.190052
The fair value above starts from this blend and is adjusted for dilution from new shares.
In the last 6 months, no officer or director bought or sold shares on the open market.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.2% (2021) → −12.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Syra Health Corp. Class A Common Stock with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 234 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−84.1% · Bottom 25%
Profitability
Return on equity (12 months)5.2% · Below median
Return on assets−32.3% · Bottom 25%
Net margin (12 months)1.6% · Below median
Operating margin (12 months)10.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)23.0% · Top 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)86.0× · Priciest 25%
P/B5.31× · Priciest 25%
P/S (12 months)1.38× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 34
FUTURE (revenue growth)100· sector 31
PAST (return on equity)21· sector 32
HEALTH (low debt)0· sector 90
DIVIDEND (yield)0· sector 39
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Syra Health Corp. Class A Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/SYRA
Frequently asked questions
Is Syra Health Corp. Class A (SYRA) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $0.1275 versus a price of $0.8010, about 84% lower (overvalued).
What is the fair value of SYRA?
Our model-based fair value for Syra Health Corp. Class A is $0.1275 (as of Nov 8, 2026), built from audited fundamentals. The current price: $0.8010.
What is the quality score of SYRA?
Syra Health Corp. Class A has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Syra Health Corp. Class A (SYRA)?
Our model-based price target is the fair value of $0.1275 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $0.0850, optimistic scenario $0.1615. It is a calculation from audited fundamentals, not an analyst target.
What is the Syra Health Corp. Class A Common Stock stock forecast for 2026?
Our models put fair value at $0.1275, about 84% lower versus a price of $0.8010 (overvalued). Cautious scenario $0.0850, optimistic scenario $0.1615. The calculation is refreshed regularly with new filings.
What is the revenue of Syra Health Corp. Class A (SYRA)?
Syra Health Corp. Class A reported trailing-twelve-month revenue of about $8.1M (latest available figure, as of Nov 8, 2026).
What is the intrinsic value of Syra Health Corp. Class A (SYRA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Syra Health Corp. Class A it is $0.1275 per share (as of Nov 8, 2026), against a price of $0.8010. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Syra Health Corp. Class A Common Stock stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SYRA trades above its calculated fair value: price $0.8010, fair value $0.1275, a gap of about −84% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SYRA?
No. The price is what the market pays today ($0.8010); the fair value is what the company's own numbers justify ($0.1275). For Syra Health Corp. Class A the two are $0.6735 per share apart. That gap is exactly why we show both numbers side by side.
How much is Syra Health Corp. Class A Common Stock worth?
The market values Syra Health Corp. Class A at about $11.1M (market capitalisation, as of Nov 8, 2026). Per share that is $0.8010; our models calculate a fair value of $0.1275 per share.
What do the bullish and bearish scenarios say about SYRA?
Our models span a range for Syra Health Corp. Class A: cautious scenario $0.0850, base $0.1275, optimistic $0.1615 per share (as of Nov 8, 2026, price $0.8010). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SYRA?
Syra Health Corp. Class A trades at a price-to-earnings ratio of 86.0 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.1275 is built from several models across several years. Other multiples: P/B 5.3, P/S 1.4.
How solid is the balance sheet of Syra Health Corp. Class A (SYRA)?
Balance-sheet figures for Syra Health Corp. Class A (as of Nov 8, 2026): return on equity 5.2%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is SYRA from its 52-week high?
Syra Health Corp. Class A trades at $0.8010, about 24% below its 52-week high of $1.05 and 1,235% above the low of $0.0600 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.1275 is for.
Which stocks are comparable to Syra Health Corp. Class A Common Stock?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Syra Health Corp. Class A Common Stock stock attractive at the current price?
The data as of Nov 8, 2026: price $0.8010, calculated fair value $0.1275 (−84%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SYRA calculated?
We run Syra Health Corp. Class A through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.1275 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Syra Health Corp. Class A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Syra Health Corp. Class A (SYRA)?
The closing price on Nov 6, 2026 was $0.8010. Our model-based fair value is $0.1275, about 84% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Syra Health Corp. Class A Common Stock right now?
The price sits above even our optimistic bull case ($0.1615). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0850 to $0.1615) leaves room in how you read the outcome.
Key figures of Syra Health Corp. Class A
How large is the market capitalisation of Syra Health Corp. Class A (SYRA)?
The market capitalisation of Syra Health Corp. Class A is $11.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Syra Health Corp. Class A (SYRA)?
The price-to-sales ratio of Syra Health Corp. Class A is 1.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Syra Health Corp. Class A (SYRA)?
The net margin of Syra Health Corp. Class A is 1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Syra Health Corp. Class A (SYRA)?
The return on equity (ROE) of Syra Health Corp. Class A is 5.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Syra Health Corp. Class A (SYRA)?
On an EBIT basis the return on assets of Syra Health Corp. Class A is −56.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Syra Health Corp. Class A (SYRA)?
The operating margin of Syra Health Corp. Class A is 10.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Syra Health Corp. Class A (SYRA)?
Revenue at Syra Health Corp. Class A is growing +23.0% versus a year earlier (3y avg +8.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Syra Health Corp. Class A (SYRA) generate?
The free cash flow of Syra Health Corp. Class A is −$448K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Syra Health Corp. Class A (SYRA) hold?
Syra Health Corp. Class A holds more cash than debt, $1.5M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Syra Health Corp. Class A Common Stock in the live analysis
One click puts Syra Health Corp. Class A Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 8, 2026
